scholarly journals Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial

2015 ◽  
Vol 16 (3) ◽  
pp. 257-265 ◽  
Author(s):  
Naiyer A Rizvi ◽  
Julien Mazières ◽  
David Planchard ◽  
Thomas E Stinchcombe ◽  
Grace K Dy ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Immune Checkpoint ◽  
Immune Checkpoint Inhibitor ◽  
Checkpoint Inhibitor ◽  
Small Cell ◽  
Phase 2 ◽  
Small Cell Lung

scholarly journals Impact of bowel movement condition on immune checkpoint inhibitor efficacy in patients with advanced non‐small cell lung cancer

2019 ◽  
Vol 10 (3) ◽  
pp. 526-532 ◽  
Author(s):  
Yuki Katayama ◽  
Tadaaki Yamada ◽  
Keiko Tanimura ◽  
Akihiro Yoshimura ◽  
Takayuki Takeda ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Immune Checkpoint ◽  
Immune Checkpoint Inhibitor ◽  
Bowel Movement ◽  
Checkpoint Inhibitor ◽  
Small Cell ◽  
Small Cell Lung ◽  
Movement Condition
Sign in / Sign up

Export Citation Format

Share Document